Activity of Sotrovimab against BQ.1.1 and XBB.1 Omicron sublineages in a hamster model

The successive emergence of SARS-CoV-2 Omicron variants has completely changed the modalities of use of therapeutic monoclonal antibodies. Recent in vitro studies indicated that only Sotrovimab has maintained partial activity against BQ.1.1 and XBB.1. In the present study, we used the hamster model...

Descripción completa

Detalles Bibliográficos
Autores principales: Driouich, Jean-Sélim, Bernadin, Ornéllie, Touret, Franck, de Lamballerie, Xavier, Nougairède, Antoine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Authors. Published by Elsevier B.V. 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10191698/
https://www.ncbi.nlm.nih.gov/pubmed/37207822
http://dx.doi.org/10.1016/j.antiviral.2023.105638

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10191698/
https://www.ncbi.nlm.nih.gov/pubmed/37207822
http://dx.doi.org/10.1016/j.antiviral.2023.105638

Ejemplares similares